NewAmsterdam’s cholesterol-lowering therapy shows Alzheimer’s promise

NewAmsterdam's obicetrapib diminished levels of p-tau217, an Alzheimer's biomarker, in patients with certain types of CVD. Obicetrapib diminished levels of p-tau217 in patients with certain types of CVD. NewAmsterdam reported data from the BROADWAY trial at AAIC 2026. Credit: sasirin pamai / Shutterstock.com. NewAmsterdam’s low-density lipoprotein (LDL) cholesterol-lowering therapy, obicetrapib, has shown promise in diminishing a key biomarker of Alzheimer’s disease – potentially signifying the drug’s role in the preventative setting. This is evidenced by the results of a post hoc responder analysis within a sub-study of the Phase III BROADWAY trial (NCT05142722). In the trial, the drug triggered a…

Source: Clinical Trials Arena